Abstract
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Biological Therapy / methods*
-
Biosimilar Pharmaceuticals / therapeutic use*
-
Canada
-
Chemistry, Pharmaceutical / methods
-
DNA / metabolism
-
Drug Costs
-
Drug Industry / trends
-
Humans
-
Infliximab
-
Patient Safety
-
Recombination, Genetic
-
Rheumatology / trends
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Biosimilar Pharmaceuticals
-
DNA
-
golimumab
-
Infliximab